IL28B polymorphisms strongly predict spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. A recent study proposed a 32-base pair deletion in the CC-chemokine receptor 5 (CCR5) gene (CCR5-D32) interacting with the IL28B polymorphisms to influence spontaneous HCV clearance. The aim of this study was to clarify the role of CCR5-D32 in treatmentinduced clearance of chronic hepatitis C (CHC). A cross-sectional cohort of 813 Caucasian patients with CHC genotype 1 (365 responders and 448 non-responders) who had received standard of care dual therapy with interferon (IFN)-a and ribavirin (RBV) was genotyped for the CCR5-D32 and IL28B polymorphisms to examine their interaction with respect to treatment response. CCR5-D32 did not influence treatment-induced recovery to IFN-a/RBV in CHC, and did not improve prediction of sustained virological response in the context of the IL28B polymorphisms in a multivariate model. CCR5-D32 homozygotes were significantly more frequent in those with CHC than healthy controls in the European cohorts (2.9% vs 0.4%, Po0.0001), but not in Australians of European ancestry. In conclusion, CCR5-D32 does not influence treatment response in the context of IL28B polymorphisms. Although CCR5-D32 may affect viral clearance within closely controlled geographical and genetic environments, we found no effect in larger cohorts treated with dual therapy.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of blood-borne hepatitis with an estimated worldwide prevalence of 3%. 1 Chronic infection causes hepatic inflammation eventually resulting in fibrosis and cirrhosis, and ultimately liver failure (reviewed in Hoofnagle 2 ). Cytokines and chemokines are key players in this process through a complex network of interactions that regulate innate and adaptive immune responses to viral infection, and recruitment of inflammatory cells to the liver. 3 Importantly, lymphocytes infiltrating HCV-infected livers have been shown to express high levels of the CC-chemokines CCL3 (macrophagic inflammatory protein 1a), CCL4 (macrophagic inflammatory protein 1b), CCL5 (regulated upon activation, normal T cell expressed and secreted) and their receptor, CC-chemokine receptor 5 (CCR5), suggesting a T helper cell type 1-mediated antiviral response by the host to the virus. 4 Several studies have linked HCV proteins to the expression of CCR5 ligands: Soo et al. 5 showed that the expression of fulllength HCV led to the induction of both CCR5 messenger RNA and protein in HeLa, Huh7 and HepG2 cell lines. An increase in CCL5 levels by CD8 þ T cells was reported to be related to the HCV E2 protein. 6 Finally, chronic HCV infection has been shown to lead to reduced surface expression of CCR5 on peripheral blood T cells. 7 CCR5 has been previously identified as the major coreceptor for human immunodeficiency virus type 1.
8 A 32-bp deletion in exon 4 of CCR5 (CCR5-D32) leads to truncation and loss of function of the receptor. 9 Homozygosity for this deletion confers high-level (but not complete) resistance to human immunodeficiency virus type 1 infection, whereas heterozygotes show delayed progression to acquired immune deficiency syndrome. 10, 11 An increased frequency of CCR5-D32 homozygosity was observed in HCV-infected individuals compared with healthy controls (7.8% vs 1.0%). 12 In a later Irish study, the authors found that CCR5-D32 was significantly associated with increased spontaneous clearance. 13 Recently, Nattermann et al.
14 have shown, in a very well-defined patient cohort (n ¼ 396) infected with HCV genotype 1 from a 1 Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia; single source, that CCR5-D32 was associated with a decrease in spontaneous viral clearance. Importantly, this effect seemed to be due to an interaction of CCR5-D32 with the recently described IL28B rs12979860 polymorphism, which has also been shown to influence spontaneous recovery from HCV infection. 15, 16 As IL28B polymorphisms are currently the strongest host genetic markers to predict treatment-induced clearance of HCV infection, [17] [18] [19] [20] we designed this study to examine for a possible interaction between the CCR5-D32 mutation and the two most predictive IL28B polymorphisms, rs8099917 and rs12979860, with respect to treatment-induced clearance of HCV infection.
RESULTS
When compared with healthy controls, patients with chronic HCV infection had a significantly increased frequency of CCR5-D32 homozygosity (Table 1 ; P ¼ 0.006). The association was due to the European cohort, with an increase in CCR5-D32 homozygous subjects (2.9% vs 0.4%; P ¼ 0.0006) and a decrease in heterozygous subjects (11.3% vs 18.0%; P ¼ 0.0015). Further, the enrichment of CCR5-D32 homozygous European Caucasian subjects with chronic hepatitis C (CHC) was quadruple that of what would have been expected based on the Hardy-Weinberg equilibrium (Po0.0001).
For treatment response to standard dual therapy (interferon (IFN)-a/ribavirin (RBV)), there was no significant difference between sustained virological responders (SVR) and non-SVR patients (NSVR), with respect to the frequency of CCR5-D32 genotype distribution or allele frequency (Table 2 and Figure 1) .
In order to examine whether the combination of the CCR5-D32 deletion with IL28B SNPs, rs12979860 and rs8099917, improves prediction of treatment-induced HCV clearance, we used logistic regression modelling, as previously described.
14, 21 We found no evidence for any two-way interactions between either of the two IL28B SNPs individually or in combination with CCR5-D32 for NSVR, even though both the IL28B SNPs individually were significantly associated with treatment response (Table 3) . CCR5-D32 and IL28B polymorphisms in HCV infection V Suppiah et al
DISCUSSION
The aim of this study was to establish whether there is an interaction between IL28B polymorphisms and CCR5-D32 with respect to predicting treatment-induced clearance of chronic HCV infection. Our results clearly show that (A) CCR5-D32 does not directly influence treatment response of HCV genotype 1 to treatment with IFN-a and RBV and (B) there is no interaction between IL28B genotypes and CCR5-D32 in this context. This is in line with previous, substantially smaller studies that have not shown a direct effect of CCR5-D32 on treatment response to IFN/ RBV treatment. [21] [22] [23] [24] [25] [26] [27] As we have previously shown in a small cohort of patients, the outcome of IFN monotherapy, but not dual therapy, may be affected by CCR5-D32. 21 The lack of a CCR5-D32 association in that and the current cohort may be due to a RBV effect. The impact of IL28B might not be masked by RBV, suggesting a much stronger role for variants of this gene in treatment outcome. Of note, age, viral load and gender were significantly different between responders and non-responders (data not shown; Po0.05). These clinical parameters are well known to be different between responders and nonresponders. 28, 29 It is well known that a major problem with clinical studies involving CCR5-D32 is that patient source does influence the CCR5-D32 frequency; CCR5-D32 has been mainly described in Caucasian populations and is subject to a strong Northern to Southern European decline in frequency. 30 Co-exposure to HIV, for which CCR5-D32 homozygosity confers a significant degree of resistance, may introduce another possible selection bias, as HIV is transmitted via similar routes to HCV. Interestingly enough, similar to our published data, 12 there was a statistical difference in the CCR5-D32 polymorphism frequency between healthy controls and chronically infected patients, probably because of patient heterogeneity and variability in co-exposure to HIV in the different populations. However, it is clear that that CCR5-D32 (either on its own or in combination with IL28B) does not influence treatment outcome from dual therapy. Significant, but opposite, associations of CCR5-D32 with spontaneous recovery were identified in two cohorts, one East German the other Irish, both from single source outbreaks and with geographically and socioeconomically analogous backgrounds. 13, 14 This suggests that a weak (compared with IL28B) effect of CCR5-D32 on spontaneous recovery may be observed in genetically well-defined contexts. More importantly, irrespective of these biases, the SVR and NSVR patients were subject to similar preselection criteria for therapy and despite this, CCR5-D32 did not impact on treatment-induced HCV clearance in our large multicenter cohort, nor was there a significant interaction between IL28B and CCR5-D32.
CCR5-D32 presents an attractive target for study in terms of HCV pathogenesis; HCV infection induces IFN-a 31 and one of the IFN-induced genes is CCR5.
32 CCR5 is expressed on T helper cell 1 cells and facilitates the migration of T cells primed by antigenic molecules. It has been observed previously that in HCV patients, lymphocytes infiltrating the liver show an increased expression of CCR5. 4 The presence of the CCR5-D32 deletion might result in a reduced expression of CCR5 in these patients, impairing their activation and migration to the infected liver. These mechanisms may be the reason why CCR5-D32 deletion may be involved in spontaneous clearance and possibly in response to IFN monotherapy. 21 RBV, however, has been postulated to exploit a novel innate mechanism to potentiate the antiviral effects of 
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V Suppiah et al IFN-a, 33 which may also involve a bias favouring the T helper cell 1 immune response. 34 In our multicenter cohort, the combination of RBV with IFN-a clearly overrode any potential effect of the CCR5-D32 deletion, whereas IL28B remained a strong predictive marker, as previously reported. [17] [18] [19] [20] We cannot exclude the possibility that an influence of the CCR5-D32 polymorphism with a small effect size was not discerned, given the cohort size of our study. However, such an effect is likely to have minimal clinical impact, as our NSVR/SVR population size had 90% chance to detect effect sizes of odds ratio of 2.0.
In summary, CCR5-D32 did not influence treatment response to treatment with IFN-a/RBV, and there was no significant interaction with IL28B genotypes. This suggests that CCR5-D32 is not relevant for treatment-induced clearance of HCV, and that therefore CCR5 expression is likely not essential in this process. New powerful direct acting antivirals for difficult-to-treat HCV genotype 1 infection are currently being introduced and will likely reduce the impact of host genetics on treatment response. 35 In view of the fact that CCR5 inhibitors are now available for HIV treatment, this is an important observation, as our data suggest that neither genetic nor drug-induced impairment of CCR5 signalling is likely to impair the efficacy of anti-HCV therapy in patients with HIV/HCV coinfection. Indeed, a recent study in HIV/HCV-coinfected patients reported no significant changes in viral titres or liver function tests during a short-term course of a CCR5 inhibitor. 36 
MATERIALS AND METHODS Subjects
Ethical approval was obtained from the Human Research Ethics Committees of Sydney West Area Health Service and the University of Sydney. All other sites had ethical approval from their respective ethics committees. Written informed consent was obtained from all participants. Characteristics of the study cohorts have been described in Table 4 . Briefly, all treated patients were Caucasian and infected with genotype 1, the majority of these patients received pegylated IFN and RBV, and had virological response determined 6 months after completion of therapy. The diagnosis of CHC was based on appropriate serology and presence of HCV RNA. Patients received therapy for 48 weeks except if there was less than a 2 log drop in HCV RNA after 12 weeks therapy. Patients were excluded if they were coinfected with HIV or HBV. The control data was obtained from previous studies done on healthy individuals from the same geographical region as the patients in this study. [37] [38] [39] [40] Genotyping The CCR5 D32 deletion was genotyped using high resolution melt, as described previously. 41 IL28B data presented in this study have been previously published. 16 
Statistical analysis
The w 2 test or Fisher's test where appropriate were used to examine differences in gender, genotype and allele frequencies between SVR vs NSVR, and CHC (that is, NSVR plus SVR) vs healthy controls. The MannWhitney test was used to compare the age and BMI between the two groups of patients. P-values o0.05 (two-sided) were regarded as significant. The relationships between CCR5-D32 and IL28B SNPs, rs8099917 and rs12979860, were investigated using logistic regression. Significance of all models was assessed by likelihood ratio tests. Analysis was carried out in R software (http://www.r-project.org; v2.12). CCR5-D32 and IL28B polymorphisms in HCV infection V Suppiah et al
